溶瘤病毒治疗的发展：从基因修饰到联合治疗。
Development of oncolytic virotherapy: from genetic modification to combination therapy.
机构信息
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.
Yantai Yuhuangding Hospital, Qingdao University, Yantai, 264000, China.
出版信息
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
Abstract
Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.
摘要
溶瘤病毒治疗（OVT）是一种利用天然或基因改造病毒选择性在恶性肿瘤细胞中复制并杀死肿瘤细胞的新型免疫治疗方法。目前已经开发出许多具有增强肿瘤靶向性、抗肿瘤疗效和安全性的基因改造溶瘤病毒（OV），其中一些已经在临床试验中进行了评估。将 OVT 与其他免疫疗法相结合可以显著提高抗肿瘤疗效。在这项工作中，我们回顾了野生型病毒在 OVT 中的应用和 OV 基因改造的策略。我们还回顾和讨论了 OVT 与其他免疫疗法的联合应用。
相似文献
1
Development of oncolytic virotherapy: from genetic modification to combination therapy.溶瘤病毒治疗的发展：从基因修饰到联合治疗。
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
2
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.溶瘤病毒免疫治疗：脑胶质瘤治疗的新选择
Front Immunol. 2021 Oct 5;12:721830. doi: 10.3389/fimmu.2021.721830. eCollection 2021.
3
Oncolytic viruses and their application to cancer immunotherapy.溶瘤病毒及其在癌症免疫治疗中的应用。
Cancer Immunol Res. 2014 Apr;2(4):295-300. doi: 10.1158/2326-6066.CIR-14-0015.
4
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.溶瘤病毒治疗已发展为肿瘤免疫治疗的第四代。
J Transl Med. 2023 Jul 25;21(1):500. doi: 10.1186/s12967-023-04360-8.
5
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.溶瘤病毒联合癌症免疫治疗：开创新一代癌症治疗。
Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020.
6
Oncolytic Virus-Driven Biotherapies from Bench to Bedside.溶瘤病毒驱动的生物疗法从实验室到临床。
Small. 2023 Jun;19(23):e2206948. doi: 10.1002/smll.202206948. Epub 2023 Mar 6.
7
Genetic modification of oncolytic viruses to enhance antitumor immunity.对溶瘤病毒进行基因改造以增强抗肿瘤免疫力。
Methods Enzymol. 2020;635:231-250. doi: 10.1016/bs.mie.2019.05.017. Epub 2019 Jun 11.
8
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.IL-21 武装增强了单纯治疗和联合治疗中溶瘤痘苗病毒的抗肿瘤活性。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001647.
9
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.确定免疫检查点阻断与溶瘤病毒疗法的有效联合方案。
Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17.
10
Application of oncolytic virus in tumor therapy.溶瘤病毒在肿瘤治疗中的应用。
J Med Virol. 2023 Apr;95(4):e28729. doi: 10.1002/jmv.28729.
引用本文的文献
1
Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis.溶瘤病毒疗法治疗恶性肿瘤患者的比较安全性和疗效：一项系统评价、荟萃分析和贝叶斯网络荟萃分析
EClinicalMedicine. 2025 Jul 19;86:103362. doi: 10.1016/j.eclinm.2025.103362. eCollection 2025 Aug.
2
Oncolytic Viruses as a Novel Therapeutic Approach for Colorectal Cancer: Mechanisms, Current Advances, and Future Directions.溶瘤病毒作为一种治疗结直肠癌的新型方法：作用机制、当前进展及未来方向
Cancers (Basel). 2025 May 31;17(11):1854. doi: 10.3390/cancers17111854.
3
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.间充质干细胞治疗多发性硬化症的最新进展：临床应用与挑战
Front Cell Dev Biol. 2025 Feb 3;13:1517369. doi: 10.3389/fcell.2025.1517369. eCollection 2025.
4
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.溶瘤病毒治疗脑膜转移的挑战与策略。
J Transl Med. 2024 Nov 5;22(1):1000. doi: 10.1186/s12967-024-05794-4.
5
Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges.纳米工程武装的溶瘤病毒驱动抗肿瘤反应：进展与挑战
MedComm (2020). 2024 Oct 10;5(10):e755. doi: 10.1002/mco2.755. eCollection 2024 Oct.
6
Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape.用于肝细胞癌的溶瘤病毒疗法：一种强大的免疫治疗前景。
World J Gastrointest Oncol. 2024 Jul 15;16(7):2867-2876. doi: 10.4251/wjgo.v16.i7.2867.
7
OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.儿科大脑中的 OV 调节剂：当前状态、联合策略、局限性和未来方向。
Int J Mol Sci. 2024 May 3;25(9):5007. doi: 10.3390/ijms25095007.
8
Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.溶瘤病毒疗法联合不同抗肿瘤方法治疗脑胶质瘤。
Int J Mol Sci. 2024 Feb 7;25(4):2042. doi: 10.3390/ijms25042042.
9
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.微卫星不稳定癌症中PD(L)-1阻断之外：免疫共抑制受体靶向治疗的现状
Cancers (Basel). 2024 Jan 9;16(2):281. doi: 10.3390/cancers16020281.
10
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.肿瘤溶瘤病毒治疗癌症：挑战与优化前景。
Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023.
本文引用的文献
1
Tumour-intrinsic resistance to immune checkpoint blockade.肿瘤内在的免疫检查点阻断耐药性。
Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30.
2
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.在转移性黑色素瘤患者中，随着病变大小的增加，替莫唑胺拉帕替尼（T-VEC）治疗的疗效降低。
Ann Surg Oncol. 2019 Dec;26(13):4633-4641. doi: 10.1245/s10434-019-07691-3. Epub 2019 Aug 14.
3
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.溶瘤病毒：癌症免疫治疗的前奏。
BioDrugs. 2019 Oct;33(5):485-501. doi: 10.1007/s40259-019-00367-0.
4
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.针对非肌肉浸润性膀胱癌的 ICAM-1 靶向免疫治疗 - 柯萨奇病毒 A21（CVA21）作为溶瘤剂的 I 期临床试验。
Clin Cancer Res. 2019 Oct 1;25(19):5818-5831. doi: 10.1158/1078-0432.CCR-18-4022. Epub 2019 Jul 4.
5
A review of chimeric antigen receptor T-cells in lymphoma.嵌合抗原受体 T 细胞在淋巴瘤中的研究进展。
Expert Rev Hematol. 2019 Jul;12(7):551-561. doi: 10.1080/17474086.2019.1629901. Epub 2019 Jun 19.
6
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.Delta-24-RGD 溶瘤病毒在小儿脑胶质瘤和 DIPG 小鼠模型中引发抗肿瘤作用。
Nat Commun. 2019 May 28;10(1):2235. doi: 10.1038/s41467-019-10043-0.
7
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.TG6002的增强肿瘤特异性，一种在参与核苷酸代谢的两个基因中缺失的武装溶瘤痘苗病毒。
Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27.
8
Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.基于溶瘤病毒的细胞因子表达以改善脑肿瘤和实体瘤中的免疫活性
Mol Ther Oncolytics. 2019 Mar 20;13:14-21. doi: 10.1016/j.omto.2019.03.001. eCollection 2019 Jun 28.
9
Poxvirus oncolytic virotherapy.痘病毒溶瘤病毒疗法。
Expert Opin Biol Ther. 2019 Jun;19(6):561-573. doi: 10.1080/14712598.2019.1600669. Epub 2019 Apr 4.
10
Recombinant adenoviruses expressing apoptin suppress the growth of MCF‑7 breast cancer cells and affect cell autophagy.表达凋亡素的重组腺病毒抑制 MCF-7 乳腺癌细胞的生长并影响细胞自噬。
Oncol Rep. 2019 May;41(5):2818-2832. doi: 10.3892/or.2019.7077. Epub 2019 Mar 18.
Zotero 插件